Rathbones Group PLC Has $1.42 Million Stock Position in Edwards Lifesciences Corporation $EW

Rathbones Group PLC decreased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 81.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,695 shares of the medical research company’s stock after selling 71,276 shares during the period. Rathbones Group PLC’s holdings in Edwards Lifesciences were worth $1,423,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Edwards Lifesciences by 0.5% in the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock worth $5,472,147,000 after acquiring an additional 365,581 shares during the last quarter. Wellington Management Group LLP boosted its stake in Edwards Lifesciences by 4.9% during the third quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock worth $1,617,959,000 after buying an additional 977,933 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Edwards Lifesciences by 8.1% during the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after buying an additional 1,423,365 shares in the last quarter. Jennison Associates LLC boosted its stake in Edwards Lifesciences by 19.6% during the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock worth $1,085,574,000 after buying an additional 2,287,783 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in Edwards Lifesciences by 111.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after buying an additional 4,805,819 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.5%

Shares of NYSE:EW opened at $80.80 on Wednesday. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The company’s fifty day moving average is $81.53 and its 200-day moving average is $81.93. The company has a market capitalization of $46.59 billion, a PE ratio of 44.16, a P/E/G ratio of 2.11 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. During the same quarter in the prior year, the firm posted $0.59 EPS. The firm’s revenue for the quarter was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 22,680 shares of the business’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total value of $1,818,028.80. Following the sale, the vice president owned 21,266 shares in the company, valued at approximately $1,704,682.56. The trade was a 51.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $80.98, for a total transaction of $82,518.62. Following the completion of the sale, the vice president owned 33,934 shares in the company, valued at $2,747,975.32. This represents a 2.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 74,077 shares of company stock worth $6,165,444. Corporate insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on EW. Canaccord Genuity Group set a $87.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, December 17th. Robert W. Baird set a $90.00 price target on shares of Edwards Lifesciences in a research note on Monday, January 12th. BTIG Research reiterated a “buy” rating and set a $103.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Truist Financial set a $89.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, February 11th. Finally, Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.96.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.